Login
$ZNTL
$1.63 +$0.03 (1.87%) After hours

$ZNTL 8-K/A SEC Filings

Filed On Filing
19 Dec 2024 8-K/A: Departure/Election of Directors or Officers; Compensation

On December 17, 2024, the Board appointed Mr. Myers as a member of the Compensation Committee of the Board (the "Compensation Committee"), effective immediately.

11 Apr 2022 8-K/A: Regulation FD Disclosure

On April 8, 2022, the Company issued a press release announcing initial efficacy and safety data from the ongoing Phase 1b trial of ZN-c3 in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian cancer,...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support